Novel Science

Cirmtuzumab

Publications

Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies (Rule et al, Br J Haem 2017) 

Cirmtuzumab inhibits ibrutinib-resistant, Wnt5a-induced Rac1 activation and proliferation in mantle cell  lymphoma (Yu et al., Oncotarget 2018)

Phase 1 Trial: Cirmtuzumab Inhibits ROR1 Signaling and Stemness Signatures in Patients with Chronic Lymphocytic Leukemia (Choi et al, Cell Stem Cell, 2018)

Inhibition of chemotherapy resistant breast cancer stem cells by a ROR1 specific antibody (Zhang et al., PNAS 2019)

Ovarian Cancer Stem Cells Express ROR1, Which Can Be Targeted  for Anti-Cancer-Stem-Cell  Therapy (Zhang et al., PNAS 2014)

Conference Presentations

Phase 1/2 Study of Cirmtuzumab and Ibrutinib in Mantle Cell Lymphoma (MCL) or Chronic Lymphocytic Leukemia (CLL)

Phase 1/2 Study of Cirmtuzumab and Ibrutinib in Mantle Cell Lymphoma (MCL) or Chronic Lymphocytic Leukemia (CLL) - VIDEO

A Phase 1b Trial of Cirmtuzumab and Paclitaxel in Locally Advanced/Unresectable or Metastatic Her2 Negative Breast Cancer (Shatsky et al., AACR 2021 Virtual Annual Meeting)

Inhibition of Ovarian and Endometrial Cancer Cell Proliferation by an Anti-ROR1 Monoclonal Antibody (Liu et al., AACR 2021 Virtual Annual Meeting)

Cirmtuzumab, an Anti-ROR1 Antibody, in Combination with Ibrutinib: Clinical Activity in Mantle Cell Lymphoma (MCL) or Chronic Lymphocytic Leukemia (CLL) from a Phase 1/2 Study (Lee et al., ASH 2020 Virtual Annual Meeting)

 Clinical Activity of Cirmtuzumab, an Anti-ROR1 Antibody, in Combination with Ibrutinib; Interim Results of a Phase 1b/2 Study in Mantle Cell Lymphoma (MCL) or Chronic Lymphocytic Leukemia (CLL) (Lee et al., ASCO 2020 Virtual Annual Meeting)

Cirmtuzumab, a ROR1 Targeted Mab, Reverses Cancer Stemness, and Its Combination with Ibrutinib Is Safe  and Effective: Planned Analysis of the CIRLL Phase 1/2 Trial for CLL and MCL (Choi et al,. ASH Annual  Meeting 2019)

 A Phase 1b Trial of Cirmtuzumab and Paclitaxel in Locally Advanced /Unresectable or Metastatic Her2  Negative Breast Cancer (Shatsky et al., San Antonio Breast Cancer Symposium 2019)

TK216

Publications

Inhibition of the oncogenic fusion protein EWS-FLI1 causes G2-M cell cycle arrest and enhanced vincristine sensitivity in Ewing’s sarcoma (Zöllner et al., Science Signaling 2017)

YK-4-279 Effectively Antagonizes EWS-FLI1 Induced Leukemia in a Transgenic Mouse Model (Minas et al., Oncotarget 2015)

A Small Molecule Inhibitor of ETV1, YK-4-279, Prevents Prostate Cancer Growth and Metastasis in a Mouse Xenograft Model (Rahim et al., PLoS One 2014)

A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing’s sarcoma (Erzikan et al., Nature Medicine 2009)

Conference Presentations

TK216 for Relapsed/Refractory Ewing Sarcoma - Interim Phase 1/2 Results

TK216 for Relapsed/Refractory Ewing Sarcoma - Interim Phase 1/2 Results - VIDEO

TK216 Phase 1 Study in Metastatic, Relapsed/Refractory Ewing Sarcoma (Ludwig, CTOS 2020)

A Phase 1, Dose Escalation Study of Intravenous TK216 in Patients with Relapsed or Refractory Ewing Sarcoma (Meyers, CTOS 2019)

The ETS inhibitors YK-4-279 and TK216 interfere with SPIB and synergize with lenalidomide in diffuse large B cell lymphoma of the activated B cell-like type (ABC DLBCL) (Chung et al., ASH Annual Meeting 2017)

CAR-T

Publications

The  Onco-Embryonic Antigen ROR1 Is Expressed by a Variety of Human Cancers (Zhang et al. , Am  J Pathol 2012)

Conference Presentations

Preclinical Evaluation of Anti-ROR1 CAR T-cells Employing a ROR1 Binding scFv Derived From the Clinical Stage mAb Cirmtuzumab (Prussak et al., 2020 ASCO-SITC Clinical Immuno-Oncology Symposium)